Article Text

Download PDFPDF
Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis
  1. Lucile Regard1,2,
  2. Clémence Martin1,2,
  3. Leila Zemoura3,
  4. Virginie Geolier1,
  5. Edouard Sage4,
  6. Pierre-Régis Burgel1,2
  1. 1 Paris Descartes University, Sorbonne Paris Cité, Paris, France
  2. 2 Pulmonary Department and Adult Cystic Fibrosis Center, Cochin Hospital, Paris, France
  3. 3 Pathology Department, Foch Hospital, Suresnes, France
  4. 4 Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France
  1. Correspondence to Dr Pierre-Régis Burgel, Paris Descartes University, Sorbonne Paris Cité, Paris 75014, France; pierre-regis.burgel{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Tertiary lymphoid structures (TLS) are usually absent in normal lungs, but peribronchial TLS are found in the lungs of patients with bronchiectasis or cystic fibrosis (CF).1 Recently, our group reported studies in mice showing that persistent bacterial infection induced peribronchial TLS, suggesting that chronic infection is a major trigger of lymphoid neogenesis in CF airways.1 However, roles of TLS in the pathogenesis of CF lung disease remain unknown and could include beneficial antimicrobial effects and/or autoimmune responses leading to tissue damage and disease worsening.2 Like secondary lymphoid organs, TLS exhibit B cell area containing follicular dendritic cells (FDC) and germinal centres, surrounded by T cells and high endothelial venules (HEV).2 Rituximab, a chimeric monoclonal antibody targeting CD20+ B cells, is used as treatment for malignant lymphoproliferative disorders and for autoimmune diseases3 and has also been used in highly sensitised patients undergoing solid organ transplantation.4 This strategy was once believed to be beneficial for sensitised lung transplant recipients but was abandoned years ago due to results showing that rituximab-based desensitisation protocol did not reduce pretransplant anti-HLA antibodies.5 In the present study, we took advantage of bronchial explants collected in two patients with CF who had received rituximab and human polyclonal intravenous immunoglobulin for high HLA-sensitisation prior to lung transplantation to examine the effects of rituximab on peribronchial TLS. Our hypothesis was that rituximab therapy, which …

View Full Text


  • Handling editor Dhirendra Govender.

  • Contributors LR, CM, PRB designed the study. LR, CM, VG acquired the data. LZ, ES contributed to sample collection. LR and PRB wrote the manuscript. All authors reviewed the data and the final manuscript.

  • Funding This work was funded by Legs Poix-Chancellerie des Universités de Paris and Vaincre la Mucoviscidose, Paris, France.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval The study was approved by the local ethics committee (CPP Ile de France II; #1072) for the use of samples of human origin.

  • Provenance and peer review Not commissioned; externally peer reviewed.